A citation-based method for searching scientific literature

Agata Mikolajczyk, Filip Mitula, Delfina Popiel, Bozena Kaminska, Maciej Wieczorek, Jerzy Pieczykolan. Cancers (Basel) 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Growth arrest-specific gene 6 transfer promotes mesenchymal stem cell survival and cardiac repair under hypoxia and ischemia via enhanced autocrine signaling and paracrine action.
Shengshuai Shan, Zhenyu Liu, Tangmeng Guo, Min Wang, Shaobo Tian, Yanqing Zhang, Kun Wang, Huabo Zheng, Xiaofang Zhao, Peiyuan Zuo,[...]. Arch Biochem Biophys 2018
11
100

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Justin F Gainor, Alice T Shaw, Lecia V Sequist, Xiujun Fu, Christopher G Azzoli, Zofia Piotrowska, Tiffany G Huynh, Ling Zhao, Linnea Fulton, Katherine R Schultz,[...]. Clin Cancer Res 2016
754
100

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma.
Francesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, Lorenza Rimassa, Gianluca Masi, Massimo Iavarone, Fabio Marra, Ingrid Garajova, Maria Pia Brizzi, Bruno Daniele,[...]. Liver Cancer 2021
13
100

Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts.
Jonas Stenhoff, Björn Dahlbäck, Sassan Hafizi. Biochem Biophys Res Commun 2004
95
100

Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.
Rachel M A Linger, Amy K Keating, H Shelton Earp, Douglas K Graham. Expert Opin Ther Targets 2010
122
100

Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.
Pearly Shuyi Ng, Klement Foo, Sandra Sim, Gang Wang, Chuhui Huang, Li Hong Tan, Anders Poulsen, Boping Liu, Doris Hui Ying Tee, Nur Huda Binte Ahmad,[...]. Bioorg Med Chem 2021
1
100

The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.
Yun Beom Sang, Joo-Hang Kim, Chang-Gon Kim, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho, Sun Min Lim. Front Oncol 2022
3
100

Gilteritinib: First Global Approval.
Sohita Dhillon. Drugs 2019
65
100

Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.
Alexis Mollard, Steven L Warner, Lee T Call, Mark L Wade, Jared J Bearss, Anupam Verma, Sunil Sharma, Hariprasad Vankayalapati, David J Bearss. ACS Med Chem Lett 2011
57
100


DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model.
Takeshi Jimbo, Mana Hatanaka, Takahiro Komatsu, Tomoe Taira, Kentaro Kumazawa, Naoyuki Maeda, Takashi Suzuki, Masahiro Ota, Noriyasu Haginoya, Takeshi Isoyama,[...]. Oncotarget 2019
17
100

TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.
Rachel M A Linger, Amy K Keating, H Shelton Earp, Douglas K Graham. Adv Cancer Res 2008
486
100

Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition.
Agnete S T Engelsen, Maria L Lotsberg, Raefa Abou Khouzam, Jean-Paul Thiery, James B Lorens, Salem Chouaib, Stéphane Terry. Front Immunol 2022
6
100

AXL kinase as a novel target for cancer therapy.
Xiaoliang Wu, Xuewen Liu, Sanjay Koul, Chang Youl Lee, Zhenfeng Zhang, Balazs Halmos. Oncotarget 2014
132
100

Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.
Sutapa Sinha, Justin Boysen, Michael Nelson, Charla Secreto, Steven L Warner, David J Bearss, Connie Lesnick, Tait D Shanafelt, Neil E Kay, Asish K Ghosh. Clin Cancer Res 2015
52
100



Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.
Jun Tang, Jia Xin Yu, Vanessa M Hubbard-Lucey, Svetoslav T Neftelinov, Jeffrey P Hodge, Yunqing Lin. Nat Rev Drug Discov 2018
237
100


axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase.
J P O'Bryan, R A Frye, P C Cogswell, A Neubauer, B Kitch, C Prokop, R Espinosa, M M Le Beau, H S Earp, E T Liu. Mol Cell Biol 1991
623
100

AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.
Samuel H Myers, Valerie G Brunton, Asier Unciti-Broceta. J Med Chem 2016
119
100

AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review.
Chih-Hung Hsu, Yi-Hsiang Huang, Shi-Ming Lin, Chiun Hsu. Liver Cancer 2022
1
100

AXL is an essential factor and therapeutic target for metastatic ovarian cancer.
Erinn B Rankin, Katherine C Fuh, Tiffany E Taylor, Adam J Krieg, Margaret Musser, Jenny Yuan, Kevin Wei, Calvin J Kuo, Teri A Longacre, Amato J Giaccia. Cancer Res 2010
156
100

Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site.
J Braunger, L Schleithoff, A S Schulz, H Kessler, R Lammers, A Ullrich, C R Bartram, J W Janssen. Oncogene 1997
125
100

The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase.
Ketan S Gajiwala, Neil Grodsky, Ben Bolaños, Junli Feng, RoseAnn Ferre, Sergei Timofeevski, Meirong Xu, Brion W Murray, Ted W Johnson, Al Stewart. J Biol Chem 2017
19
100


Gene of the month: Axl.
Matthew Brown, James R M Black, Rohini Sharma, Justin Stebbing, David J Pinato. J Clin Pathol 2016
25
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.